| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |
|
Medicine details |
|
| Medicine name | sofosbuvir / velpatasvir / voxilaprevir (Vosevi®) |
| Formulation | 600 mg film-coated tablet |
| Reference number | 3494 |
| Indication | Treatment of chronic hepatitis C virus infection in adults |
| Company | Gilead Sciences Ltd |
| BNF chapter | Infections |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 13/07/2017 |
| NICE guidance | TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C |